Cargando…

Attenuation of lipid peroxidation and atherogenic factors in diabetic patients treated with gliclazide and metformin

BACKGROUND: Diabetes is associated with oxidative stress and considered as a major risk factor for cardiac disease. We attempted to investigate the role of oral antidiabetic (OAD) agents gliclazide and metformin in lowering the lipid peroxidation and managing the risk for cardiovascular (CV) complic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banik, Sujan, Hossain, Mohammad Salim, Bhatta, Rita, Akter, Mariyam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116668/ https://www.ncbi.nlm.nih.gov/pubmed/30181759 http://dx.doi.org/10.4103/jrms.JRMS_202_17

Ejemplares similares

Effect of combined gliclazide/metformin treatment on oxidative stress, lipid profile, and hepatorenal functions in type 2 diabetic patients
por: Alsharidah, Mansour, et al.
Publicado: (2018)

The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus()
por: Wang, Hua, et al.
Publicado: (2013)

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus
por: Al-Gareeb, Ali I., et al.
Publicado: (2016)

Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ
por: Abbasi, Mehran Mesgari, et al.
Publicado: (2016)

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
por: Ristic, S, et al.
Publicado: (2006)

Simultaneous Determination of Metformin, Nateglinide and Gliclazide in Pharmaceutical Preparations Using Micellar Liquid Chromatography
por: El-Wasseef, Dalia Rashad
Publicado: (2012)

Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension
por: Sampathi, Sunitha, et al.
Publicado: (2022)

Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study
por: Nazief, Alaa Mohamed, et al.
Publicado: (2020)

Central Adiposity and Atherogenic Lipids in Saudi Diabetics
por: Khandekar, Suresh, et al.
Publicado: (1994)

Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records
por: Polavarapu, Nareen Krishna, et al.
Publicado: (2020)

Fabrication and Characterization of Gliclazide Nanocrystals
por: Ravouru, Nagaraju, et al.
Publicado: (2018)

Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide
por: Gedawy, Ahmed, et al.
Publicado: (2018)

A Supercritical Fluid Chromatography/Tandem Mass Spectrometry Method for the Simultaneous Quantification of Metformin and Gliclazide in Human Plasma
por: Agrawal, Y. K., et al.
Publicado: (2010)

Preparation and Crystallographic Analysis of Gliclazide Polymorphs
por: Rajamma, A. J., et al.
Publicado: (2015)

Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
por: Javorský, Martin, et al.
Publicado: (2013)

Brain activities of streptozotocin-induced diabetic Wistar rats treated with gliclazide: Behavioural, biochemical and histomorphology studies
por: Ekong, Moses B., et al.
Publicado: (2022)

Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial
por: Feng, Wen‐Huan, et al.
Publicado: (2018)

Acute Exfoliative Dermatitis/Erythroderma Secondary to Gliclazide
por: Al-Badawi, Saifaldeen, et al.
Publicado: (2023)

Advanced and multifaceted stability profiling of the first-line antidiabetic drugs metformin, gliclazide and glipizide under various controlled stress conditions
por: Gedawy, Ahmed, et al.
Publicado: (2020)

The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis
por: Summerhill, Volha I., et al.
Publicado: (2019)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2016)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Bioavailability and Antidiabetic Activity of Gliclazide-Loaded Cubosomal Nanoparticles
por: Nasr, Mohamed, et al.
Publicado: (2021)

Annexin A6 Polymorphism Is Associated with Pro-atherogenic Lipid Profiles and with the Downregulation of Methotrexate on Anti-Atherogenic Lipid Profiles in Psoriasis
por: Zhang, Fuxin, et al.
Publicado: (2022)

Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
por: Forouzandeh, Farshad, et al.
Publicado: (2014)

Anti-inflammation-based treatment of atherosclerosis using Gliclazide-loaded biomimetic nanoghosts
por: Karami, Zahra, et al.
Publicado: (2023)

A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy
por: Hissa, Marcelo R. Nasser, et al.
Publicado: (2015)

Novel Gliclazide Electrosprayed Nano-Solid Dispersions: Physicochemical Characterization and Dissolution Evaluation
por: Adibkia, Khosro, et al.
Publicado: (2019)

Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

The influence of physical division of tablets on the variability of release kinetics of gliclazide
por: Wójcik-Pastuszka, Dorota, et al.
Publicado: (2018)

Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2018)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
por: Cheng, Yang, et al.
Publicado: (2021)

Lipid profile and plasma atherogenic index in postmenopausal osteoporosis
por: Ersoy, Gulcin Sahin, et al.
Publicado: (2017)

Hypoglycemia with gliclazide MR in women with type 2 diabetes. A continuous glucose monitoring study
por: Vianna, André G Daher, et al.
Publicado: (2015)

Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile
por: Vrieling, Frank, et al.
Publicado: (2018)

Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN
por: Hassanein, Mohamed, et al.
Publicado: (2021)

Protective Effects of Beta Glucan and Gliclazide on Brain Tissue and Sciatic Nerve of Diabetic Rats Induced by Streptozosin
por: Alp, Harun, et al.
Publicado: (2012)

Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
por: Leiter, Lawrence A., et al.
Publicado: (2018)

Assessment of Dyslipidemia, Lipid Ratios, and Atherogenic Indices as Cardiovascular Risk Factors in Prediabetic and Diabetic Subjects
por: Rathi, Himani, et al.
Publicado: (2022)

Gliclazide: Unmasking of glucose-6-phosphate dehydrogenase deficiency: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_efajmpqig705ep2r89e9ea4i7h